Author:
Roy R,Zurakowski D,Wischhusen J,Frauenhoffer C,Hooshmand S,Kulke M,Moses M A
Publisher
Springer Science and Business Media LLC
Reference56 articles.
1. Ballehaninna U, Chamberlain R (2012) The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: an evidence based appraisal. J Gastrointest Oncol 3: 105–119.
2. Bramhall S, Stamp G, Dunn J, Lemoine N, Neoptolemos J (1996) Expression of collagenase (MMP2), stromelysin (MMP3) and tissue inhibitor of the metalloproteinases (TIMP1) in pancreatic and ampullary disease. Br J Cancer 73: 972–978.
3. Brand R, Nolen B, Zeh H, Allen P, Eloubeidi M, Goldberg M, Elton E, Arnoletti J, Christein J, Vickers S, Langmead C, Landsittel D, Whitcomb D, Grizzle W, Lokshin A (2011) Serum biomarker panels for the detection of pancreatic cancer. Clin Cancer Res 17: 805–816.
4. Brune K, Lau B, Palmisano E, Canto M, Goggins M, Hruban R, Klein A (2010) Importance of age of onset in pancreatic cancer kindreds. J Natl Cancer Inst 102: 119–126.
5. Canto M, Goggins M, Hruban R, Petersen G, Giardiello F, Yeo C, Fishman E, Brune K, Axilbund J, Griffin C, Ali S, Richman J, Jagannath S, Kantsevoy S, Kalloo A (2006) Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol 4: 766–781, quiz 665.
Cited by
65 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献